• 1
    Langholz E, Munkholm P, Davidsen M, Binder V. Course of ulcerative colitis: analysis of changes in disease activity over years. Gastroenterology 1994; 107: 311.
  • 2
    Hanauer SB, Sandborn W. Practice Parameters Committee of the American College of Gastroenterology Management of Crohn’s disease in adults. Am J Gastroenterol 2001; 96: 63543.
    Direct Link:
  • 3
    Kornbluth A, Sachar DB. Ulcerative colitis practice guidelines in adults (update): American College of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol 2004; 99: 137185.
    Direct Link:
  • 4
    Carter MJ, Lobo AJ, Travis SPL. Guidelines for the management of inflammatory bowel disease in adults. Gut 2004; 53(Suppl. V): v116.
  • 5
    Travis SP, Stange EF, Lemann M, et al. European evidence based consensus on the diagnosis and management of Crohn’s disease: current management. Gut 2006; 55(Suppl. 1): i1635.
  • 6
    Truelove SC, Witts LJ. Cortisone in ulcerative colitis: final report on a therapeutic trial. Br Med J 1955; 2: 104188.
  • 7
    Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med 1987; 317: 16259.
  • 8
    D’Haens G, Sandborn WJ, Feagan BG, et al. A review of activity indices and efficacy endpoints for clinical trials of medical therapy in adults with ulcerative colitis. Gastroenterology 2007; 132: 76386.
  • 9
    Best WR, Becktel JM, Singleton JW. Rederived values of the eight coefficients of the Crohn’s Disease Activity Index (CDAI). Gastroenterology 1979; 2: 8436.
  • 10
    Sandborn WJ, Feagan BG, Hanauer SB, et al. A review of activity indices and efficacy endpoints for clinical trials of medical therapy in adults with Crohn’s disease. Gastroenterology 2002; 122: 51230.
  • 11
    Summers RW, Switz DM, Sessions JT Jr, et al. National Cooperative Crohn’s Disease Study: results of drug treatment. Gastroenterology 1979; 2: 84769.
  • 12
    Malchow H, Ewe K, Brandes JW, et al. European Cooperative Crohn’s Disease Study (ECCDS): results of drug treatment. Gastroenterology 1984; 86: 24966.
  • 13
    Bergman L, Krause U. Postoperative treatment with corticosteroids and salazosulphapyridine (Salazopyrin) after radical resection for Crohn’s disease. Scand J Gastroenterol 1976; 11: 6516.
  • 14
    Smith RC, Rhodes J, Heatley RV, et al. Low dose steroids and clinical relapse in Crohn’s disease: a controlled trial. Gut 1978; 19: 60610.
  • 15
    Lichtenstein GR, Abreu MT, Cohen R, Tremaine W. American Gastroenterological Association Institute technical review on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease. Gastroenterology 2006; 130: 94087.
  • 16
    Singleton JW, Law DH, Kelley ML Jr, Mekhjian HS, Sturdevant RA. National Cooperative Crohn’s Disease Study: adverse reactions to study drugs. Gastroenterology 1979; 77: 87082.
  • 17
    Papi C, Festa V, Leandro G, et al. Long-term outcome of Crohn’s disease following corticosteroid-induced remission. Am J Gastroenterol 2007; 102: 8149.
    Direct Link:
  • 18
    Munkholm P, Langholz E, Davidsen M, et al. Frequency of glucocorticoid resistance and dependency in Crohn’s disease. Gut 1994; 35: 3602.
  • 19
    Faubion WA, Loftus EV, Harmsen WS, et al. The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. Gastroenterology 2001; 121: 25560.
  • 20
    Candy S, Wright J, Gerber M, et al. A controlled double blind study of azathioprine in the management of Crohn’s disease. Gut 1995; 37: 6748.
  • 21
    Pearson DC, May GR, Fick GH, et al. Azathioprine and 6-mercaptopurine in Crohn disease. A meta-analysis. Ann Intern Med 1995; 123: 13242.
  • 22
    Jewell DP, Truelove SC. Azathioprine in ulcerative colitis: final report on controlled therapeutic trial. Br Med J 1974; 4: 62730.
  • 23
    Rosenberg JL, Wall AJ, Levin B, et al. A controlled trial of azathioprine in the management of chronic ulcerative colitis. Gastroenterology 1975; 69: 969.
  • 24
    Kirk AP, Lennard-Jones JE. Controlled trial of azathioprine in chronic ulcerative colitis. Br Med J (Clin Res Ed) 1982; 284: 12912.
  • 25
    Hawthorne AB, Logan RF, Hawkey CJ, et al. Randomised controlled trial of azathioprine withdrawal in ulcerative colitis. Br Med J 1992; 305: 202.
  • 26
    Ardizzone S, Maconi G, Russo A, Imbesi V, Colombo E, Bianchi Porro G. Randomised controlled trial of azathioprine and 5-aminosalicylic acid for treatment of steroid dependent ulcerative colitis. Gut 2006; 55: 4753.
  • 27
    Ghosh S, Chaudhary R, Carpani M, Playford RJ. Is thiopurine therapy in ulcerative colitis as effective as in Crohn’s disease? Gut 2006; 55: 68.
  • 28
    Lémann M, Bonhomme P, Bitoun A, Messing B, Modigliani R, Rambaud JC. Treatment of Crohn’s disease with azathioprine or 6-mercaptopurine. Retrospective study of 126 cases.. Gastroenterol Clin Biol 1990; 14: 54854.
  • 29
    Khan ZH, Mayberry JF, Spiers N, Wicks AC. Retrospective case series analysis of patients with inflammatory bowel disease on azathioprine. A district general hospital experience. Digestion 2000; 62: 24954.
  • 30
    Sandborn W, Sutherland L, Pearson D, et al. Azathioprine or 6-mercaptopurine for inducing remission of Crohn’s disease. Cochrane Database Syst Rev 1998; 2: CD000545.
  • 31
    Feagan BG, Rachon J, Fedorak RN, et al. ; The North American Crohn’s Study Group Investigators. Methotrexate for the treatment of Crohn’s disease. N Engl J Med 1995; 332: 2927.
  • 32
    Feagan BG, Fedorak RN, Irvine EJ, et al. A comparison of methotrexate with placebo for the maintenance of remission in Crohn’s disease. North American Crohn’s Study Group Investigators. N Engl J Med 2000; 342: 162732.
  • 33
    Oren R, Arber N, Odes S, et al. Methotrexate in chronic active ulcerative colitis: a double-blind, randomized, Israeli multicenter trial. Gastroenterology 1996; 110: 141621.
  • 34
    Lichtiger S, Present DH, Kornbluth A, et al. Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Engl J Med 1994; 330: 18415.
  • 35
    Moskovitz DN, Van Assche G, Maenhour B, et al. Incidence of colectomy during long-term follow-up after cyclosporine-induced remission of severe ulcerative colitis. Clin Gastroenterol Hepatol 2006; 4: 7605.
  • 36
    Van Assche G, D’Haens G, Noman M, et al. Randomized, double-blind comparison of 4 mg/kg versus 2 mg/kg intravenous cyclosporine in severe ulcerative colitis. Gastroenterology 2003; 125: 102531.
  • 37
    Campbell S, Travis S, Jewell D. Ciclosporin use in acute ulcerative colitis: a long-term experience. Eur J Gastroenterol Hepatol 2005; 17: 7984.
  • 38
    Waljee A, Waljee J, Morris AM, Higgins PDR. Threefold increased risk of infertility: a meta-analysis of infertility after ileal pouch anal anastomosis in ulcerative colitis. Gut 2006; 55: 157580.
  • 39
    Penna C, Dozois R, Tremaine W, et al. Pouchitis after ileal pouch-anal anastomosis for ulcerative colitis occurs with increased frequency in patients with associated primary sclerosing cholangitis. Gut 1996; 38: 2349.
  • 40
    Delaney CP, Fazio VW, Remzi FH, et al. Prospective, age-related analysis of surgical results, functional outcome, and quality of life after ileal pouch-anal anastomosis. Ann Surg 2003; 238: 2218.
  • 41
    Munkholm P, Langholz E, Davidsen M, Binder V. Intestinal cancer risk and mortality in patients with Crohn’s disease. Gastroenterology 1993; 105: 171623.
  • 42
    Targan SR, Hanauer SB, Van Deventer SJ, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn’s disease. Crohn’s Disease cA2 Study Group. N Engl J Med 1997; 337: 102935.
  • 43
    Present DH, Rutgeerts P, Targan S, et al. Infliximab for the treatment of fistulas in patients with Crohn’s disease. N Engl J Med 1999; 340: 1398405.
  • 44
    Rutgeerts P, Feagan BG, Lichtenstein GR, et al. Comparison of scheduled and episodic treatment strategies of infliximab in Crohn’s disease. Gastroenterology 2004; 126: 40213.
  • 45
    Sands BE, Blank MA, Patel K, Van Deventer SJ, ACCENT II Study. Long-term treatment of rectovaginal fistulas in Crohn’s disease: response to infliximab in the ACCENT II Study. Clin Gastroenterol Hepatol 2004; 2: 91220.
  • 46
    Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trial. Lancet 2002; 359: 15419.
  • 47
    Hanauer SB, Sandborn WJ, Rutgeerts P, et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn’s disease: the CLASSIC-I trial. Gastroenterology 2006; 130: 32333.
  • 48
    Sandborn WJ, Hanauer SB, Rutgeerts PJ, et al. Adalimumab for maintenance treatment of Crohn’s disease: results of the CLASSIC II trial. Gut 2007; 56: 12329.
  • 49
    Colombel JF, Sandborn WJ, Rutgeerts P, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn’s disease: the CHARM trial. Gastroenterology 2007; 132: 5265.
  • 50
    Schroeder KW. Role of mesalazine in acute and long-term treatment of ulcerative colitis and its complications. Scand J Gastroenterol Suppl 2002; 236: 427.
  • 51
    Sninsky CA, Cort DH, Shanahan F, et al. Oral mesalamine (Asacol) for mildly to moderately active ulcerative colitis. A multicenter study. Ann Intern Med 1991; 115: 3505.
  • 52
    Sutherland LR, May GR, Shaffer EA. Sulfasalazine revisited: a meta-analysis of 5-aminosalicylic acid in the treatment of ulcerative colitis. Ann Intern Med 1993; 118: 5409.
  • 53
    Tremaine WJ, Schroeder KW, Harrison JM, et al. A randomized, double-blind, placebo-controlled trial of the oral mesalamine (5-ASA) preparation, Asacol, in the treatment of symptomatic Crohn’s colitis and ileocolitis. J Clin Gastroenterol 1994; 19: 27882.
  • 54
    Marteau P, Probert CS, Lindgren S, et al. Combined oral and enema treatment with Pentasa (mesalazine) is superior to oral therapy alone in patients with extensive mild/moderate active ulcerative colitis: a randomised, double blind, placebo controlled study. Gut 2005; 54: 9605.
  • 55
    Sachar DB. Maintenance therapy in ulcerative colitis and Crohn’s disease. J Clin Gastroenterol 1995; 20: 11722.
  • 56
    Sandborn WJ, Feagan BG. Review article: mild to moderate Crohn’s disease – defining the basis for a new treatment algorithm. Aliment Pharmacol Ther 2003; 18: 26377.
  • 57
    Tung J, Loftus EV Jr, Freese DK, et al. A population-based study of the frequency of corticosteroid resistance and dependence in pediatric patients with Crohn’s disease and ulcerative colitis. Inflamm Bowel Dis 2006; 12: 1093100.
  • 58
    Modigliani R, Mary JY, Simon JF, et al. Clinical, biological, and endoscopic picture of attacks of Crohn’s disease. Evolution on prednisolone. Groupe d’Etude Therapeutique des Affections Inflammatoires Digestives. Gastroenterology 1990; 98: 8118.
  • 59
    Cosnes J, Nion-Laurmurier I, Beaugerie L, et al. Impact of the increasing use of immunosuppressants in Crohn’s disease on the need for intestinal surgery. Gut 2005; 54: 23741.
  • 60
    Markowitz J, Grancher K, Kohn N, et al. A multicenter trial of 6-mercaptopurine and prednisolone in children with newly diagnosed Crohn’s disease. Gastroenterology 2000; 119: 895902.
  • 61
    Hommes D, Baert F, Van Assche G, et al. A randomized controlled trial evaluating the ideal medical management for Crohn’s disease (CD): top-down versus step-up strategies. Gastroenterology 2005; 128(Suppl. 2): A-577.
  • 62
    D’Haens GR, Baert F, Assche G, et al. Better outcomes with potent top-down induction therapy in recent onset Crohn’s disease. Gut 2005; 54(Suppl. VII): A17.
  • 63
    D’Haens GR, Baert F, De Vos, et al. Superior endoscopic healing with induction regimen of infliximab and azathioprine versus classic step-up therapy in newly diagnosed Crohn’s disease. Gut 2005; 54: A18.
  • 64
    Hyams J, Crandall W, Kugathasan S, et al. ; The REACH Study Group. Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn’s disease in children. Gastroenterology 2007; 132: 86373.
  • 65
    Schreiber S, Hanauer SB, Lichtenstein GR, Sandborn WJ. Superior efficacy of certolizumab pegol in early Crohn’s disease is independent of CRP status. Gastroenterology 2007; 132 (Suppl. 1): A5101 (abstract T1298).
  • 66
    Schreiber S, Reinisch W, Colombel J, et al. Early Crohn’s disease shows high levels of remission to therapy with adalimumab: sub-analysis of CHARM. Gastroenterology 2007; 132(Suppl. 1): A147 (abstract 985).
  • 67
    Lichtenstein GR, Feagan BG, Cohen RD, et al. Serious infections and mortality in association with therapies for Crohn’s disease: TREAT registry. Clin Gastroenterol Hepatol 2006; 4: 62130.
  • 68
    Remicade® Prescribing Information. Malvern, PA: Centocor, Inc., April 2007.
  • 69
    Remicade® (infliximab) Summary of Product Characteristics (SPC). January 2007.
  • 70
    Abbott Laboratories Press Release. 2007. Available at: (accessed 25 March 2007).
  • 71
    Humira® (Prescribing Information. North Chicago, IL: Abbott Laboratories, February 2008.
  • 72
    Humira® (Adalimumab) Summary of Product Characteristics (SPC). January 2008.
  • 73
    American Gastroenterological Association Clinical Practice Committee. American Gastroenterological Association medical position statement: perianal Crohn’s disease. Gastroenterology 2003; 125: 15037.
  • 74
    Sandborn WJ, Present DH, Isaacs KL, et al. Tacrolimus for the treatment of fistulas in patients with Crohn’s disease: a randomized, placebo-controlled trial. Gastroenterology 2003; 125: 3808.
  • 75
    Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005; 353: 246276.
  • 76
    Leung Y, Panaccione R, Hemmelgam B, Jones J. Exposing the weaknesses: a systematic review of azathioprine efficacy in ulcerative colitis. Dig Dis Sci 2008; 53: 145561.
  • 77
    Jarnerot G, Hertervig E, Friis-Liby I, et al. Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. Gastroenterology 2005; 128: 180511.
  • 78
    Frøslie KF, Jahnsen J, Moum BA, Vatn MH, IBSEN Group. Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort. Gastroenterology 2007; 133: 41222.